Compare Recursion Pharmaceuticals Inc (RXRX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Snap On Incorporated trades at $402.3 (market cap $21.06B). The key difference: Snap On Incorporated is far larger — about 13.8× Recursion Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.4% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SNA | |
|---|---|---|
Market Cap | $1.53B | $21.06B |
Sector | Health | Technology |
52-Week High | $6.79 | $414.97 |
52-Week Low | $2.84 | $317.79 |
Enterprise Value | $946.50M | $20.58B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong 2025 results with $5.16B revenue and $1.02B net income, maintaining robust profitability margins. Recent strategic acquisitions like Diesel Laptops for $100M aim to expand its heavy-duty diagnostics capabilities, supporting future growth.
The outlook is positive given solid fundamentals and analyst support, but risks include potential margin pressures and reliance on automotive demand. With 64.71% of analysts rating it a buy and a dividend yield supported by recent declarations, SNA presents a stable investment opportunity tempered by industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
